ÐÓ°ÉÔ­´´

Oncopeptides, based in Stockholm, shows strong potential due to its focus on developing innovative therapies for difficult-to-treat hematological diseases. Unlike traditional options like standard chemotherapy and bone marrow transplants—which often result in continued suffering and poor survival rates—Oncopeptides aims to significantly improve patient outcomes. The company's fresh approach allows it to address unmet medical needs with potentially more effective solutions. Backed by the European Investment Bank, Oncopeptides is well-positioned to advance in the treatment of hematological conditions.